HABS-HD - Core C - Clinical Core

HABS-HD临床核心(核心C)摘要 健康与老龄化大脑研究-健康差异(HABS-HD)的长期目标是建立一个 针对人群的信息精准医学为阿尔茨海默病的新治疗和预防策略 NIA AD ADRD里程碑1中要求的疾病(AD)。临床核心(核心C)将在 继续进行所有直接参与者面谈、评估、成像和其他协议组件 (家长研究及/或辅助研究)。到U19启动时，队列将由3000人组成 50岁及以上社区居住参与者(n=1,000非裔美国人[AA]，1,000墨西哥人 美国人[MA]和1000名非西班牙裔白人[nhw])。访问一次(V1)和24个月纵向V2数据将 在MA和NHW参与者中启动U19时可获得AA可用的V1数据 参与者。作为U19的一部分，我们将继续对现有队列进行为期24个月的评估，并登记 增加1500名参与者(每个种族/民族500人；年龄30-49岁)，以获得更全面的 在美国最大的三个种族/民族中检查AT(N)定义的成年期生物标记物 美国核心C负责审查分配研究诊断(医学和认知)的所有数据 并向参与者、家庭和医疗服务提供者提供反馈，作为我们回馈 参与者在知情同意过程中表明的社区。Core收集的数据 C将对所有项目至关重要，也将通过LONI向科学界提供。这个 临床核心目标如下：目标1(数据捕获)：与所有核心协作，继续遵循 关于收集、处理、编目、储存和分配人口的统一议定书， 支持总体计划目标的临床和影像数据。目标2(脑脊液亚研究)：进行脑脊液 体液(脑脊液)采集子研究。目标3(协商一致审查和反馈)：继续进行协商一致 审查以确保适当分配基于研究的临床诊断(认知和医学)和 在知情同意期间向参与者、家庭和卫生保健提供者提供反馈 进程。目标4(协作)：与核心和项目协作。目标5(脑库)：建立基础， 社区关系和未来实施HABS-HD脑库的基础设施。目标6(交叉研究 比较)：与其他AD ADRD项目和计划协作进行交叉研究比较 利用HABS-HD临床数据。与行政核心(核心A)合作，努力确保 与ADNI、WHICAP、SOL/INCA、Leads、ABC-DS、New等持续计划的交叉研究比较 点子、ADC和其他。

HABS-HD CLINICAL CORE (CORE C) ABSTRACT The long-term goal of the Health & Aging Brain Study – Health Disparities (HABS-HD) is to establish a population-specific informed precision medicine for novel treatment and prevention strategies for Alzheimer’s disease (AD) as called for in NIA AD+ADRD Milestone 1. The Clinical Core (Core C) will meet this goal by continuing to conduct all direct participant interviews, assessments, imaging, and other protocol components (parent study and/or ancillary studies). By the time of the initiation of the U19, the cohort will consist of 3,000 community-dwelling participants ages 50 and above (n=1,000 African Americans [AA], 1,000 Mexican Americans [MA], and 1,000 non-Hispanic whites [NHW]). Visit one (V1) and 24-month longitudinal V2 data will be available at initiation of the U19 among the MA and NHW participants with V1 data available for the AA participants. As part of this U19, we will continue 24-month assessments of the existing cohort as well as enroll an additional 1,500 participants (n=500 per racial/ethnic group; age 30-49) for a more comprehensive examination of AT(N) defined biomarkers across adulthood among the three largest racial/ethnic groups in the U.S. Core C is responsible for reviewing all data for assignment of research diagnoses (medical and cognitive) as well as providing feedback to participants, families and health care providers as part of our “give back” to the community as indicated during the informed consent process by the participant. The data collected by Core C will be crucial for all Projects and will also be made available to the scientific community via LONI. The Clinical Core Aims are as follows: Aim 1 (Data Capture): In collaboration with all Cores, continue to follow harmonized protocols for the collection, processing, cataloging, storage and distribution of demographic, clinical and imaging data in support of overall program goals. Aim 2 (CSF Substudy): Conduct cerebrospinal fluid (CSF) collection substudy. Aim 3 (Consensus Reviews and Feedback): Continue to conduct consensus reviews to ensure appropriate assignment of research-based clinical diagnoses (cognitive and medical) and provide feedback to participants, families and heath care providers as indicated during informed consent process. Aim 4 (Collaboration): Collaborate with Cores and Projects. Aim 5 (Brain Bank): Build foundation, community relations and infrastructure for future implementation of HABS-HD Brain Bank. Aim 6 (Cross-Study Comparisons): Work collaboratively with other AD+ADRD projects and programs for cross-study comparisons leveraging HABS-HD clinical data. In collaboration with the Administrative Core (Core A), work to ensure cross-study comparisons with ongoing initiatives such as ADNI, WHICAP, SOL/INCA, LEADS, ABC-DS, New IDEAS, ADCs and others.